Indications for TEKTURNA:
Adults and Children:
<6yrs (<20kg): not established. ≥6yrs (≥50kg): initially 150mg once daily, may increase to 300mg once daily if BP not adequately controlled. May be given with other antihypertensives (see full labeling).
Concomitant ARBs or ACEIs in diabetes. Children <2yrs of age.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting therapy or start under close supervision. Discontinue if angioedema or laryngeal edema occurs (have SC epinephrine available). Moderate renal impairment (CrCl <60mL/min): avoid concomitant ARBs or ACEIs. Monitor BP, electrolytes, and renal function periodically. Consider withholding or discontinuing if significant renal dysfunction develops. Renal artery stenosis. Severe HF. Post-MI. Diabetes. Children 2–<6yrs (<20kg): avoid. Neonates. Pregnancy: avoid. Nursing mothers: not recommended.
Direct renin inhibitor.
Avoid concomitant cyclosporine, itraconazole. Caution with NSAIDs, K+ supplements, K+ sparing diuretics, K+ containing salt substitutes; may cause hyperkalemia. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. Dual inhibition of the renin-angiotensin system with ARBs or ACEIs may increase risk of hypotension, hyperkalemia, renal function changes. Concomitant furosemide; monitor. Decreased absorption with high fat meals.
Diarrhea, hypotension, cough, rash, edema, elevated uric acid, gout, renal stones; rare: angioedema.